Aulos Bioscience Appoints Leo Redmond as Chief Financial Officer
Akero Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
Galaxy Medical and Japan Lifeline Enter Distribution Agreement For Novel Pulsed Electric Field Focal Ablation Catheter
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
Stoke Presents New Data That Demonstrate Tango Antisense Oligonucleotides Increase OPA1 Protein Production and Improve Mitochondrial Function in Cells Derived From Patients With Autosomal Dominant Optic Atrophy
Akero Therapeutics Appoints Yuan Xu to its Board of Directors
Mace Rothenberg, M.D., Joins Aulos Bioscience Board of Directors
Stoke Therapeutics Announces MHRA Authorization to Initiate Phase 1/2a Clinical Trial of STK-001 for Dravet Syndrome in the United Kingdom
Akero Therapeutics Announces First Patient Randomized for Dosing in Phase 2b Study of Efruxifermin (EFX) in F2/F3 NASH Patients (HARMONY)
Akero Announces Positive Histological Improvements in Cirrhotic NASH (F4) Patients after 16 Weeks in Extension Cohort C
Akero Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
Galaxy Medical Receives $18 Million from ATP to Advance Development of Its Novel Pulsed Electric Field Ablation Therapy for Cardiac Arrhythmias
Aulos Bioscience Appoints Aron Knickerbocker as CEO
Stoke Therapeutics Reports Full Year 2020 Financial Results and Provides Business Updates
Doug Godshall to Chair Gala Therapeutics Board of Directors
Akero Therapeutics Initiates Phase 2b HARMONY Study of Efruxifermin (EFX) for the Treatment of NASH
Gala Therapeutics Receives FDA Approval to Commence Pivotal Trial to Evaluate the RheOx™ System for Chronic Bronchitis
Galaxy Medical CENTAURI™ PEF System to be Displayed at AF Symposium Recorded Case Presentation
ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer
ATP Forms ATP V With $1 Billion in New Capital Commitments
Stoke Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Stoke Therapeutics Announces Pricing of $97.5 Million Public Offering
Stoke Therapeutics Announces Proposed Public Offering
Nereid Therapeutics Launches: ATP $50M Series A NewCo Co-Founded with Brangwynne, Pioneer of Biomolecular Condensates Field
Akero Therapeutics Reports Third Quarter 2020 Financial Results
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
Akero Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for Efruxifermin (EFX) in NASH
First Patients Treated with Galaxy Medical’s CENTAURI™ Pulsed Electric Field Cardiac Ablation System
Stoke Therapeutics Announces Plans to Move Forward With Dosing of STK-001 in Children and Adolescents in Ongoing Phase 1/2a MONARCH Study for Dravet Syndrome
Akero Therapeutics Completes Enrollment of Cohort of Cirrhotic (F4) Patients In Ongoing BALANCED Study
Akero Therapeutics To Continue Efruxifermin Development With Innovative Adaptive Phase 2b/3 Clinical Trial Design Based On FDA Written Guidance
Gala Therapeutics’ RheOx™ System Showcased at Virtual European Respiratory Society Congress
Results Published from Multicenter Study of Gala Therapeutics' Minimally Invasive RheOx™ System in Patients with Chronic Bronchitis
Preclinical Data on Stoke Therapeutics' STK-001 Published in Science Translational Medicine
STAT: 4 Questions for Neurology Startups as Venture Investors Pour Millions into the Field
Akero Therapeutics Reports Second Quarter 2020 Financial Results
Stoke Therapeutics Announces First Patient Dosed in MONARCH Study in Dravet Syndrome
Research Published in Cell Reports Medicine Highlights Potential of Akero Therapeutics' NASH Therapeutic Candidate
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Stoke Therapeutics Announces Publication of Data in Nature Communications That Support Company’s Proprietary Approach to Addressing Severe Genetic Diseases by Precisely Upregulating Protein Expression
Apple Tree Partners Founds Nine Square Therapeutics to Pioneer Novel Treatments for Movement Disorders
Akero Announces Strongly Positive Histological Data Across All Efruxifermin Dose Groups in 16-Week Phase 2a BALANCED Study in NASH Patients
Akero Therapeutics Doses First Patient in Expansion of Phase 2a Trial in NASH
Apple Tree Partners Portfolio Company Corvidia Therapeutics to be Acquired by Novo Nordisk
Stoke Therapeutics Appoints Julie Anne Smith to its Board of Directors
Braeburn Submits Request for Final Approval of BRIXADI™ (buprenorphine) Extended-Release Injection for the Treatment of Opioid Use Disorder
Stoke Presents Preclinical Data That Demonstrate In-Vitro and In-Vivo Target Engagement and Protein Upregulation in OPA1 Protein Deficiency, the Primary Cause of the Most Common Inherited Optic Nerve Disorder
All AKR-001 Dose Groups Met Week 12 Efficacy Endpoints in NASH Phase 2a BALANCED Study
Akero Therapeutics Expands Phase 2a Trial in NASH to Include Cohort of Cirrhotic Patients
Akero Therapeutics Completes Enrollment in Phase 2a Study in NASH
Stoke Therapeutics Presents Preclinical Data on Biodistribution, Target Engagement and Safety of STK-001 That Support Planned Clinical Development of STK-001 for Treatment of Dravet Syndrome
Stoke Therapeutics Presents Preclinical Data From Studies of STK-001 That Showed Improvements in Survival and Reductions in Seizure Frequency in a Mouse Model of Dravet Syndrome
​New Clinical Results from RheOxTM System for Chronic Bronchitis to be Presented at European Respiratory Society (ERS) International Congress
Gala Therapeutics Receives FDA Breakthrough Device Designation for the Minimally Invasive RheOx™ System for Chronic Bronchitis
Gala Therapeutics Receives CE Mark for its Minimally Invasive RheOx™ System for Chronic Bronchitis
Stoke Therapeutics Granted FDA Orphan Drug Designation for STK-001, an Investigational New Treatment for Dravet Syndrome
U.S. District Court Orders FDA to Reconsider Application for Final Approval of BRIXADI™ (buprenorphine) Extended-Release Injection for the Treatment of Opioid Use Disorder
Akero Therapeutics Announces Dosing of First Patient in Phase 2a Study of AKR-001 to Treat NASH (BALANCED)
Akero Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
Stoke Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Akero Therapeutics Announces Pricing of Initial Public Offering
Stoke Therapeutics Announces Pricing of Initial Public Offering
Stoke Therapeutics Appoints Jennifer Burstein to its Board of Directors
Braeburn Announces Publication of Phase 3 Study Results Showing Long-term Safety and Effectiveness of BRIXADI™ (buprenorphine) Extended-Release Injection for the Treatment of Opioid Use Disorder
Akero Therapeutics Initiates Phase 2a Clinical Trial of Investigational Therapy AKR-001 for the Treatment of NASH
Initial Study of Gala's Minimally Invasive RheOx™ Device Demonstrates Positive Results for Chronic Bronchitis Patients
Akero Therapeutics Appoints Life Sciences Investment Banking Veteran Bill White as Chief Financial Officer and Head of Corporate Development
Akero Therapeutics Appoints Industry Veteran Jane Pritchett Henderson to Board of Directors
Stoke Therapeutics Appoints Industry Veteran Stephen Tulipano as Chief Financial Officer
Stoke Therapeutics to Present on First Disease-Modifying Therapies for Genetic Epilepsies at Cowen and Company Annual Health Care Conference
Behind the Seizure™ Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures
Gala Enrolls First Subject at Temple Lung Center as Part of the US Early Feasibility Trial of RheOx™ for Chronic Bronchitis in the United States
Akero Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
Stoke Therapeutics to Present on First Precision Treatments for Genetic Epilepsies at J.P. Morgan Healthcare Conference
Braeburn Announces Tentative FDA Approval of BRIXADI™ (buprenorphine) Extended-Release Injection for the Treatment of Moderate to Severe Opioid Use Disorder
Stoke Therapeutics Expands Senior Leadership Team, Adding Deep Expertise in Regulatory Affairs and Clinical Operations
Akero Therapeutics Announces $70 Million in New Financing
Akero Therapeutics Appoints Mark Iwicki to its Board of Directors
Stoke Therapeutics Presents Data Showing Single Dose of ASO Therapy Restores Normal Protein Levels in Animal Model of Genetic Epilepsy
Stoke Therapeutics to Present New Data on Lead Program at American Epilepsy Society's 2018 Annual Meeting
Gala Enrolls First Subjects in an Early Feasibility Study of RheOx™ for Chronic Bronchitis in the United States
Alexion Completes Acquisition Of Syntimmune
Stoke Therapeutics Announces $90 Million Series B Financing to Advance Novel Oligonucleotide Medicines
Akero Therapeutics Expands Leadership Team
Alexion to Acquire Syntimmune
CAM2038 Receives Positive CHMP Opinion for the Treatment of Opioid Dependence in Europe
Braeburn Announces Positive Top-line Phase 3 Results for CAM2038 in Chronic Low Back Pain Patients Previously on Long-term Daily Opioid Therapy
Gala Presents Positive Results from First-In-Human Clinical Trial of RheOx™ in Chronic Bronchitis at the European Respiratory Society
Stoke Therapeutics Appoints Biotech Veteran Arthur Tzianabos, Ph.D. to Board of Directors
Andrew Cheng, MD, PhD Joins Akero Therapeutics as President and Chief Executive Officer
Data From First-In-Human RheOx™ Bronchial Rheoplasty Trial to be Presented at the European Respiratory Society
Braeburn Announces PDUFA Date for CAM2038 for the Treatment of Opioid Use Disorder
Gala Therapeutics Receives FDA IDE Approval for a US Early Feasibility Study of Its RheOx™ System to Treat Chronic Bronchitis
Akero Therapeutics Closes $65 Million Series A Financing to Advance New Treatments for Serious Metabolic Diseases
Braeburn Resubmits New Drug Application for CAM2038 for Opioid Use Disorder
Startup seeks answers to insidious form of epilepsy
Braeburn Announces Publication of Positive Phase 3 Results For Long-Acting Buprenorphine For Treatment Of Opioid Use Disorder in JAMA Internal Medicine
Stoke Therapeutics Expands Leadership Team, Building on Deep Expertise in Oligonucleotide Chemistry and Rare Disease Research and Development
Braeburn Launches Brave Action
Braeburn Announces Completion of $110 Million Financing
Braeburn Announces FDA Advisory Committee Recommends Approval of CAM2038 Buprenorphine Depot for the Treatment of Opioid Use Disorder